HRP20040939A2 - Treatment of gastroparesis - Google Patents

Treatment of gastroparesis

Info

Publication number
HRP20040939A2
HRP20040939A2 HRP20040939A HRP20040939A2 HR P20040939 A2 HRP20040939 A2 HR P20040939A2 HR P20040939 A HRP20040939 A HR P20040939A HR P20040939 A2 HRP20040939 A2 HR P20040939A2
Authority
HR
Croatia
Prior art keywords
glp
val8
compound
gastroparesis
use according
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Joseph Anthony Jakubowski
Thurman Dwight Mckinney
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HRP20040939A2 publication Critical patent/HRP20040939A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HRP20040939 2002-04-10 2003-03-27 Treatment of gastroparesis HRP20040939A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10
PCT/US2003/008457 WO2003087139A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Publications (1)

Publication Number Publication Date
HRP20040939A2 true HRP20040939A2 (en) 2004-12-31

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040939 HRP20040939A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Country Status (18)

Country Link
US (1) US20050164925A1 (enExample)
EP (1) EP1496924A4 (enExample)
JP (1) JP2005530732A (enExample)
KR (1) KR20040098063A (enExample)
CN (1) CN1735423A (enExample)
AU (1) AU2003220403A1 (enExample)
BR (1) BR0308904A (enExample)
CA (1) CA2480858A1 (enExample)
EA (1) EA200401345A1 (enExample)
EC (1) ECSP045345A (enExample)
HR (1) HRP20040939A2 (enExample)
IL (1) IL164266A0 (enExample)
MX (1) MXPA04009929A (enExample)
NO (1) NO20044815L (enExample)
NZ (1) NZ535684A (enExample)
PL (1) PL373658A1 (enExample)
WO (1) WO2003087139A2 (enExample)
ZA (1) ZA200408111B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
JP4960700B2 (ja) 2003-07-21 2012-06-27 メタキュアー リミティド 疾患を治療し、血糖を制御する際に使用するための胃腸処置方法および装置
EP1670515A2 (en) * 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
EP1793891B1 (en) 2004-08-18 2011-11-09 Metacure Limited Monitoring, analysis, and regulation of eating habits
EP1868679B1 (en) 2005-02-17 2017-05-03 MetaCure Limited Non-immediate effects of therapy
EP1880298B1 (en) 2005-02-17 2016-07-13 Metacure Limited Charger with data transfer capabilities
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
ES2484796T3 (es) 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
US8463404B2 (en) 2005-03-24 2013-06-11 Metacure Limited Electrode assemblies, tools, and methods for gastric wall implantation
ATE533403T1 (de) * 2005-03-24 2011-12-15 Metacure Ltd Drahtlose leitungen für magen-darm-trakt- anwendungen
US8301256B2 (en) 2005-06-02 2012-10-30 Metacure Limited GI lead implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
EP2007804B1 (en) * 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
WO2008139463A2 (en) * 2007-05-09 2008-11-20 Metacure Ltd. Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
EP2482840A4 (en) * 2009-08-07 2013-06-26 Mannkind Corp VAL (8) GLP-1 COMPOSITION AND METHOD FOR THE TREATMENT OF REAGENTS AND / OR IRRITATION SYNDROME
PL2525834T3 (pl) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Hormony wzrostu o przedłużonej skuteczności in-vivo
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
PH12012502018A1 (en) 2010-04-30 2018-03-21 Sanwa Kagaku Kenkyusho Co Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
AU2003220403A1 (en) 2003-10-27
PL373658A1 (en) 2005-09-05
JP2005530732A (ja) 2005-10-13
MXPA04009929A (es) 2006-03-10
EP1496924A4 (en) 2007-05-30
CA2480858A1 (en) 2003-10-23
US20050164925A1 (en) 2005-07-28
ZA200408111B (en) 2005-10-07
IL164266A0 (en) 2005-12-18
NO20044815L (no) 2005-01-07
NZ535684A (en) 2006-03-31
BR0308904A (pt) 2005-05-03
EA200401345A1 (ru) 2005-08-25
EP1496924A2 (en) 2005-01-19
WO2003087139A3 (en) 2004-01-08
CN1735423A (zh) 2006-02-15
ECSP045345A (es) 2006-04-19
KR20040098063A (ko) 2004-11-18
WO2003087139A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
US20050164925A1 (en) Treatment of gastroparesis
Maselli et al. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity
US7259233B2 (en) Chronic treatment regimen using glucagon-like insulinotropic peptides
JP5645339B2 (ja) 摂食行動の修正
JP5792925B2 (ja) 過剰体重を防止または治療するためのオキシンソモジュリン
Feinglos et al. Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes
KR101383493B1 (ko) 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및아밀린 효능제
AU2002239384A1 (en) Chronic treatment regimen using glucagon-like insulinotropic peptides
RS67258B1 (sr) Upotreba dugodelujućih glp-1 peptida
Tschöp et al. Seeking satiety: From signals to solutions
Gasbjerg et al. Proglucagon-derived peptides: human physiology and therapeutic potential
KR20080106950A (ko) 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및 아밀린 효능제
Wallberg-Henriksson Interaction of exercise and insulin in type II diabetes mellitus
AU2003262552A1 (en) Use of human growth hormone in multiple system atrophy
TW202506170A (zh) 糖尿病之治療
Näslund et al. Drug targets modulating the gut-appetite-metabolism axis
Kemp Posted on June 3, 2012 by haridallas Insulinotropic Glucagon-Like Peptides Joel F. Habener
Gladson DRUG TREATMENT FOR OSTEOPOROSIS
Tan Regulation of metabolism and food intake by enteropancreatic hormones
Bajaj Incretin Hormones-Pathophysiological Basis of Therapeutic Intervention
HK1162356A (en) Modification of feeding behaviour and weight control by oxyntomodulin
HK1080010B (en) Modification of feeding behaviour and weight control by oxyntomodulin

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060314

Year of fee payment: 4

OBST Application withdrawn